Supporting Published Evidence for Nerium EHT, PP2A and its Ingredients.

Nerium EHT was developed at Signum Biosciences in collaboration with Princeton University (Department of Molecular Biology). Research was funded in part by the National Institute of Health, the Michael J. Fox Foundation, and the Alzheimer’s Drug Discovery Foundation.

Nerium EHT – A Breakthrough Discovery

Only NeriumEHT contains EHT™ (Eicosanoyl-5-hydroxytryptamide). Our one-of-a-kind proprietary ingredient is a naturally occurring mix of bioactive molecules isolated from coffee that helps to fortify, protect and enhance your mind. EHT™ modulates PP2A, a key master regulator protein and improves performance, including restoration of cognitive and motor deficits in animal models of neurodegeneration.

How does EHT™ Protect?

  • Helps protect neuronal structural integrity to allow robust signaling by modulating PP2A
  • Reduces damage caused by inflammation
  • Guards against oxidative stress

How does EHT™ Enhance?

  • Optimizes PP2A activity
  • Increases cognitive function and provides neuroprotection
  • Enhances memory circuit connections and slows neurodegeneration

Additional Support

Chronic inflammation is an unfortunate condition caused by a number of factors including brain injury (CTE), aging, toxins (smoking/drinking), and stroke. Chronic inflammation can cause significant neuronal damage in the brain with an excessive release of cytokines and inflammatory mediators causing additional damage. NeriumEHT protects your neurons and promotes brain health by reducing inflammation and pro-inflammatory cytokines.

The Following Studies Demonstrate EHT Provides Cognitive Support.

  1. Therapeutic benefits of a component of coffee in a rat model of Alzheimer’s disease. Basurto-Islas G, Blanchard J, Tung YC, Fernandez JR, Voronkov M, Stock M, Zhang S, Stock JB, Iqbal, K. Neurobiol Aging. 2014. (Epub ahead of print). PMID: 25034344
  2. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson’s Disease. Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM. Neurotherapeutics. 2013. 10(1):143-53. PMID: 23296837
  3. Enhanced phosphatase activity attenuates a-synucleinopathy in a mouse model. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM. J Neurosci. 2011. 11:31(19):6963-71. PMID: 21562258

The Following Studies Demonstrates That One or More of the Components of Nerium EHT Provides Cognitive Support and/or Protection.

  1. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. De Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Int J Geriatr Psychiatry. 2012. 27(6):592-600 PMID: 21780182
  2. Oral folic acid and vitamin B12 supplementation to prevent cognitive decline in community dwelling older adults with depressive symptoms – the Beyond Ageing Project: a randomized controlled trial. Walker JG, Batterham PJ, Mackinnon AJ, Jorm, AF, Hickie I, Fenech M, Kljakovic M, Crisp D, Christensen H. Am J Clin Nutr. 2012. Jan; 95(1):194-203. PMID: 22170358
  3. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. PLoS One. 2010. 5(9):e12244.PMID: 20838622
  4. A randomized double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s disease. Connelly PJ, Prentice NP, Cousland G, Bonham J. Int J Geriatr Psychiatry. 2008. 23(2):155-60. PMID: 17600848
  5. Enhancement of learning and memory by elevating brain magnesium. Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G. Neuron 2010. 65(2):165-177. PMID: 20152124

 The Structural Integrity of Your Brain

An essential component to keeping your brain young is the condition of its structural integrity. Neurons are the building blocks of the nervous system and it’s vital to keep the connections robust, between all the neurons in your brain. A major protein that is responsible for maintaining these connections is known as PP2A (Protein phosphatase 2A).

PP2A and Tau

Your brain is made up of a network of cells known as neurons. Neurons are all connected by axons, the structure of which is maintained by tau proteins binding to microtubules that run along the length of the axon. The PP2A system is a process that binds to tau, ensuring the microtubules stay strong, maintains robust connections and thus healthy neurons.

Between aging, poor diet, lack of exercise and concussive damage, PP2A activity is compromised, leading to hyperphosphorylation of tau. In other words, the binding process of tau to the microtubules is compromised causing them to weaken and separate. When this happens, the neurons are destabilized making them unhealthy.

PP2A and Alpha-synuclein

Alpha-synuclein is another protein which lives at the tip of each neuron in a structure known as the presynaptic terminal, an essential part of how neurons communicate with one another.
Similar to tau, alpha-synuclein is programmed by the same master protein regulator— PP2A. Just like tau, when PP2A activity is compromised, it can cause the hyperphosphorylation of alpha-synuclein which may lead to irreversible damage and neurodegenerative disease.

So now that you understand how essential the PP2A system is to overall brain health and function, what can you do about it?

EHT™, the proprietary ingredient in NeriumEHT, is a naturally occurring botanically derived mix of bioactive molecules that helps to regulate the PP2A system. Therefore, it assists in the stabilization of brain integrity, restores motor function, promotes balanced brain chemistry and improves overall brain health.

The following studies demonstrate PP2A is an important regulator in neurodegeneration and cognition

  1. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Sontag JM, Sontag E. Front Mol Neurosci. 2014. 11;7:16. PMID: 24653673
  2. How it all started: tau and protein phosphatase 2A. Liu C., Gotz J. J Alzheimer’s Dis. 2013. 37(3):483-494. PMID: 23948891
  3. Alpha-Synuclein phosphorylation as a therapeutic target in Parkinson’s disease. Braithwaite SP, Stock JB, Mouradian M. Rev Neurosci. 2012. 23(2):191-198. PMID: 22499677
  4. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3ß. Martin L, Page G, Terro F. Neurochem Int. 2011. 59(2):235-250. PMID: 21672577
  5. Role of PP2A in Alzheimer’s disease. Rudrabhatla P, Pant HC. Curr Alzheimer Res. 2011. 8(6):623-632. PMID: 21605044
  6. PP2A: a novel druggable target for Alzheimer’s disease. Voronkov M, Braithwaite SP, Stock JB. Future Med Chem. 2011. 3(7):821-833. PMID: 21644827
  7. B vitamin deficiency promotes tau phosphorylation through regulation of GSK3ß and PP2A. Nicolia V, Fuso A, Cavallaro RA, Di Luzio A, Scarpa S. J Alzheimers Dis. 2010. 19(3):895-907. PMID: 20157245
  8. The carboxy-terminal fragment of inhibitor-2 of PP2A induces Alzheimer disease pathology and cognitive impairment. Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K. FASEB J. 2010. 24(11):4420-4432. PMID: 20651003
  9. Inhibition of GSK3ß downregulates total tau proteins in cultured neurons and its reversal by the blockade of PP2A. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F. J Brain Res. 2009. 3(1252):66-75. PMID: 19071093
  10. Structural mechanism of demethylation and inactivation of PP2A. Xing Y, Li Z, Chen Y, Stock JB, Jeffrey PD, Shi Y. Cell. 2008. 133:154-63. PMID: 18394995
  11. PP2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. Sontag E, Craig VN, Sontag JM, Arrastia RD, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T. Journal of Neuroscience. 2007. 27(11):2751-2759 PMID: 17360897
  12. Downregulation of PP2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, White C. Journal of Neuropath & Exp Neurology. 2004. 62(10):1080-1091 PMID: 15535135
  13. PP2A methylation: a link between elevated plasma homocysteine and Alzheimer’s Disease. Vafai S, Stock JB. FEBS Lett. 2002. 518, 1-4. PMID: 11997007
Opt In Image
Sign Up for Our Monthly Nerium Giveaway

Retain that youthful, healthy glow for life,  and look ten years younger. Sign up below to learn more about NeriumAD and we'll enter you into our monthly giveaway.

4 replies
  1. Deborah Guthrie
    Deborah Guthrie says:

    Is there any negative reactions with medications like,Warfairin,Metoprolol ,or with any other medicines that is known of. What about can this be safely give to a person that has had a stroke 3 weeks ago that’s on the above medicines ?

    Reply
    • Mark
      Mark says:

      Hi Deborah,

      I started EHT about a year ago & you can get it from my site if you would like.

      As far as medications I’m ADHD & on Meds for that with the 2 or 3 EHT supplement pills a day. So far no side affects & from what both my doctors say is that it’s safe with any Medications.

      Also my brother started taking it 2 weeks after his stroke and he thinks it’s Amazing due to he didn’t have many of the abilities prior haha

      Anyway I didn’t see a reply so I hope this helps!

      Sincerely,
      Marky

      Reply

Trackbacks & Pingbacks

  1. […] For a more detailed view of review of Nerium EHT or to read the published white papers on Nerium EHT visit Supporting Published Evidence for Nerium EHT, PP2A and its Ingredients. […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *